

Medi-Cal Rx Monthly Bulletin

August 1, 2025

Updates have been made or are scheduled for one or more of the lists located on the <u>Contract Drugs & Covered Products Lists</u> page and the <u>Medi-Cal Rx Provider Manual</u> on the <u>Medi-Cal Rx Web Portal</u>. Sign up for the <u>Medi-Cal Rx Subscription Service</u> to be notified when the <u>Medi-Cal Rx Monthly Bulletin</u> is posted.

- 1. Updates to the Medi-Cal Rx Contract Drugs List
- 2. Updates to the Medi-Cal Rx Provider Manual
- 3. <u>Changes to Extended Duration Prior Authorization Status for Select Maintenance</u> Medications
- 4. <u>Medical Supplies: Updates to the List of Contracted Blood Pressure Monitors and Cuffs, Effective September 1, 2025</u>

1. Updates to the Medi-Cal Rx Contract Drugs List

The following updates have been made to the <u>Medi-Cal Rx Contract Drugs List</u> (CDL) and to the <u>Medi-Cal Rx Diagnosis Crosswalk</u> *.

Drug Name	Description
Avutometinib/Defactinib	Added to the CDL with labeler restriction (LR).
* Dupilumab	Additional diagnosis codes added to the <i>Medi-Cal Rx Diagnosis Crosswalk</i> .
Mitomycin	Additional formulation (intravesical kit) added to the CDL with LR.
Taletrectinib	Added to the CDL with LR.

2. Updates to the Medi-Cal Rx Provider Manual

The following updates/additions have been made to the Medi-Cal Rx Provider Manual.

Section	Update Description
Section 3.3.3 – Remittance Advice (RA)	Rearranged and refined language in introductory paragraphs for flow.
Section 3.3.3.1 – Paper RAs	Section was formerly titled Paper RA Example.
	 Updated some existing paper remittance advice (RA) fields and descriptions in the Paper RA Field Descriptions table.
	• Added new paper RA fields and descriptions to the <i>Paper RA Field Descriptions</i> table.
	• Removed some paper RA fields and descriptions from the Paper RA Field Descriptions table.
	Added a new example of sample paper RAs.
	Removed previous examples of sample paper RAs.
Section 3.3.3.2 – Electronic RAs (NEW!)	Added language regarding the HIPAA-compliant 835 Electronic Data Interchange (EDI) electronic remittance advice (ERA).
	Added a table of the industry standard loops and segments with descriptions utilized by Medi-Cal Rx along with some specific rules applied for the Medi-Cal Rx-included data.
Section 3.3.3.2.1 – Signing up for ERAs (NEW!)	Added language regarding how to sign up for ERAs and how to maintain the ERA enrollment.

Section	Update Description	
Section 3.3.3.2.2 – Viewing ERAs (NEW!)	 Added language regarding how to access, download, and view ERAs delivered through the Medi-Cal Rx Secured Provider Portal. 	
Section 4.6.1 – Legend and Non-Legend Drugs	Added language regarding reimbursement for outpatient drugs (including over-the-counter [OTC] drugs and physician administered drugs [PADs]) covered by Medi-Cal Rx.	
	Added language regarding pharmacy claims submitted with a date of service (DOS) on or after July 18, 2025.	
Section 4.6.7 – Compound Prescriptions	Added language that paper compound claims may use the California Specific Compound Pharmacy Claim Form (30-4) or Universal Claim Form (UCF).	
	Added language regarding pharmacy claims submitted with a DOS on or after July 18, 2025.	
Section 4.6.7.1 – Compound (Injection/Infusion) Pricing	Added language regarding Gross Amount Due (GAD) and Usual and Customary (U&C) charges for claims with a DOS on or after July 18, 2025: ingredient cost, compounding fee, sterilization fee, and professional dispensing fee.	
	Added Systematized Nomenclature of Medicine (SNOMED) values.	
Section 4.6.7.2 – Compound (Non-Injection/Non-Infusion) Pricing	 Added language regarding GAD and U&C charges for claims with a DOS on or after July 18, 2025: ingredient cost, compounding fee, sterilization fee, and professional dispensing fee. Added SNOMED values. 	
Section 17.1 – COVID-19 Vaccine Administration Reimbursement	 Added language regarding GAD and U&C charges for claims with a DOS on or after July 18, 2025: ingredient cost, compounding fee, sterilization fee, and professional dispensing fee. Added language regarding pharmacy claims submitted 	
	with a DOS on or after July 18, 2025.	
Section 18.1 – Mpox Vaccine Reimbursement	Added language regarding GAD and U&C charges for claims with a DOS on or after July 18, 2025: ingredient cost, compounding fee, sterilization fee, and professional dispensing fee.	
	Added language regarding pharmacy claims submitted with a DOS on or after July 18, 2025.	

3. Changes to Extended Duration Prior Authorization Status for Select Maintenance Medications

What Pharmacy Providers and Prescribers Need to Know

Effective September 1, 2025, the following drugs will not be eligible for extended duration/multi-year prior authorizations (PAs).

Drug Name
Xolair® (omalizumab)
Cystagon® (cysteamine bitartrate)
Procysbi® (cysteamine bitartrate)

Claims submitted for these drugs without an approved PA with a DOS on or after September 1, 2025, will deny with **Reject Code 75 – Prior Authorization Required**. A PA request will need to be submitted for coverage considerations.

What Pharmacy Providers and Prescribers Need to Do

- Consider alternate covered therapies that may not require a PA, if clinically appropriate.
 Refer to the <u>Medi-Cal Rx Approved NDC List</u> on the <u>Medi-Cal Rx Web Portal</u>.
- If a change in therapy is not appropriate, beginning September 1, 2025, submit a PA request via one of the approved Medi-Cal Rx submission methods. Refer to the alert titled *Prior Authorization Submission Reminders*, which was last updated on June 3, 2025.

4. Medical Supplies: Updates to the List of Contracted Blood Pressure Monitors and Cuffs, Effective September 1, 2025

The <u>List of Contracted Blood Pressure Monitors and Cuffs</u> has been updated on the <u>Medi-Cal Rx Web Portal</u>. The effective date of the changes is September 1, 2025.

The following product no longer requires a PA:

Manufacturer	Product Name	Medi-Cal 11-digit Billing Number (NDC)	MAC per each
A&D Medical	UA-789AC Extra Large Blood Pressure Monitor Upper Arm (16.5"-23.6"), A/C adapter, 1 EA (each); contains 1 BP machine and 1 cuff	93764060062	\$86.32

Contractors have guaranteed that Medi-Cal Rx providers may purchase, upon request, for dispensing to eligible Medi-Cal members, covered products at or below the Maximum Acquisition Cost (MAC). Providers can locate MAC price suppliers by calling manufacturer phone numbers referenced in the *Lists* on the Contract Drugs & Covered Products Lists page on the Medi-Cal Rx Web Portal.

Medi-Cal members denied coverage of a requested Medi-Cal Rx product have the right to a State Hearing. A State Hearing may be requested by contacting the California Department of Social Services, State Hearings Division, at the following address:

State Hearings

P.O. Box 944243, MS 21-37 Sacramento, CA 94244-2430

Toll Free: 1-800-743-8525 or 1-855-795-0634

Fax: 1-833-281-0905

Medi-Cal members have the right and are encouraged to consult their primary care provider or prescriber to determine if an appropriate substitute product is available and covered by Medi-Cal Rx.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.